AN2 Therapeutics, Inc. (ANTX) Revenue History
Annual and quarterly revenue from 2019 to present
ANTX Revenue Over Time (2019–2025)
ANTX Revenue Growth History
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
ANTX Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 13, 2026, AN2 Therapeutics, Inc. (ANTX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
ANTX's historical revenue data shows various trends over time.
Peer Comparison
Compared to Healthcare sector peers — including INSM (+115.1% YoY), SPRO (+22.8% YoY), and ENTA (+7.4% YoY). Compare ANTX vs INSM →
ANTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 ANTXCurrent | $0 | - | - | - | |
 INSM | $606M | +115.1% | +29.8% | -194.0% | |
 SPRO | $60M | +22.8% | +44.9% | -0.0% | |
 ENTA | $65M | +7.4% | -11.8% | -130.7% | |
 IDYA | $219M | +3118.1% | +62.1% | -72.8% |
ANTX Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-38,109,000 | - |
| 2024 | $0 | - | $0 | - | $-54,554,000 | - |
| 2023 | $0 | - | $0 | - | $-69,635,000 | - |
| 2022 | $0 | - | $-77,000 | - | $-42,262,000 | - |
| 2021 | $0 | - | $0 | - | $-21,574,000 | - |
| 2020 | $0 | - | $0 | - | $-7,284,000 | - |
| 2019 | $0 | - | $0 | - | $-31,068,000 | - |
What if you invested $1,000 in ANTX back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in ANTX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ANTX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationANTX vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowANTX — Frequently Asked Questions
Quick answers to the most common questions about buying ANTX stock.
Is ANTX's revenue growth accelerating or slowing?
ANTX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ANTX's revenue history from 2019 to 2026?
AN2 Therapeutics, Inc. (ANTX) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ANTX's long-term revenue growth rate (CAGR)?
AN2 Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ANTX.
Why does ANTX's quarterly revenue fluctuate?
ANTX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. AN2 Therapeutics, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is ANTX's revenue distributed by segment?
ANTX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ANTX's revenue compare to industry peers?
AN2 Therapeutics, Inc. (ANTX) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.